drugset / Trial / NCT04911127
Therapeutic Response of Cannabidiol in Rheumatoid Arthritis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study will randomly assign Rheumatoid Arthritis (RA) patients on stable RA therapy to either placebo or cannabidiol (CBD). The overall goal of this proposal is to examine the efficacy and safety of CBD treatment as adjunctive to the medical management of RA patients.
Timeline
- Start
- 2021-10-05
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cannabidiol | Other / unclassified | 200 mg | Oral |
| Subject | Cannabidiol | Other / unclassified | 400 mg | Oral |